Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
38.14
-0.58 (-1.51%)
After Hours: 38.14 0.00 (0.00%)
Sep 29, 4:15PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.74 - 38.71
52 week 31.84 - 41.66
Open 38.55
Vol / Avg. 1.46M/2.18M
Mkt cap 10.57B
P/E 41.65
Div/yield     -
EPS 0.92
Shares 277.42M
Beta 1.02
Inst. own 101%
Nov 2, 2016
Q4 2016 Hologic Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 13, 2016
Hologic Inc at Morgan Stanley Global Healthcare Conference
Aug 11, 2016
Hologic Inc at Canaccord Genuity Growth Conference - Webcast
Jul 27, 2016
Q3 2016 Hologic Inc Earnings Call - Webcast
Jul 27, 2016
Q3 2016 Hologic Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 11.82% 4.87%
Operating margin 19.43% 14.51%
EBITD margin - 36.04%
Return on average assets 4.66% 1.64%
Return on average equity 16.64% 6.35%
Employees 5,290 -
CDP Score - -

Address

250 Campus Dr
MARLBOROUGH, MA 01752-3020
United States - Map
+1-508-2632900 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays. Its Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection for mammography and minimally invasive breast biopsy devices, breast biopsy site markers and breast biopsy guidance systems. Its GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. Its Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers.

Officers and directors

Stephen P. MacMillan Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Peter J. Valenti III Division President- Breast and Skeletal Health
Age: 52
Bio & Compensation  - Reuters
Thomas A. West Division President- Diagnostics
Age: 52
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Allison Bebo Senior Vice President - Human Resources
Bio & Compensation  - Reuters
John M. Griffin General Counsel
Age: 55
Bio & Compensation  - Reuters
Elaine S. Ullian Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 62
Bio & Compensation  - Reuters